The drug nivolumab (trade name: Opdivo) has been approved in Germany since November 2016 for the treatment of Hodgkin's lymphoma. It is a treatment option for adults if their cancer returns after stem cell transplantation and antibody treatment with brentuximab vedotin, or if these treatments were not effective enough.
The name “Hodgkin’s lymphoma” is used to describe a whole group of lymphatic system cancers caused by the uncontrolled growth of mutated white blood cells (lymphocytes). These lymphocytes can spread through the body via lymph vessels. Early symptoms of Hodgkin's lymphoma may include constantly swollen lymph nodes. If this type of cancer reaches an advanced stage, it may also spread to organs such as the liver, spleen or bone marrow.
The aim of treatment with nivolumab is to stimulate the immune system to fight the cancer.
Nivolumab is given every two weeks in the form of an infusion (an IV drip), entering the bloodstream directly through a vein. The infusion takes about 60 minutes. The exact dose is determined by the patient's body weight.
Treatment is stopped if the disease gets worse or if very severe side effects arise.
If Hodgkin's lymphoma returns after stem cell transplantation, one option may be another stem cell transplantation.
If that can’t be done, further treatment will depend on factors such as the previous treatments tried. It is individually modified by the doctor.
In 2017, the Institute for Quality and Efficiency in Health Care (IQWiG, Germany) wanted to find out whether nivolumab has any advantages or disadvantages for people with Hodgkin's lymphoma when compared with the current standard treatments.
But the manufacturer did not provide any suitable data with which to do the assessment.
This information summarizes the main results of a review produced by the Institute for Quality and Efficiency in Health Care (IQWiG, Germany). The review was commissioned by the German Federal Joint Committee (G-BA) as part of the “early benefit assessment of medications.” On the basis of the review and the hearings received, the G-BA passed a resolution on the added benefit of nivolumab (Opdivo).
Institute for Quality and Efficiency in Health Care (IQWiG, Germany). Nivolumab (Hodgkin lymphoma) - Benefit assessment according to §35a Social Code Book V. Dossier assessment; commission A16-76. March 30, 2017. (IQWiG reports; volume 501).
IQWiG health information is written with the aim of helping
people understand the advantages and disadvantages of the main treatment options and health
Because IQWiG is a German institute, some of the information provided here is specific to the German health care system. The suitability of any of the described options in an individual case can be determined by talking to a doctor. informedhealth.org can provide support for talks with doctors and other medical professionals, but cannot replace them. We do not offer individual consultations.
Our information is based on the results of good-quality studies. It is written by a team of health care professionals, scientists and editors, and reviewed by external experts. You can find a detailed description of how our health information is produced and updated in our methods.